Yourgene Health PLC - Manchester, England-based molecular diagnostics group - Signs five-year contract extension with Illumina Inc. The contract is a restated licence and supply agreement for Yourgene's sequencing based NIPT in vitro diagnostic products, which will now run until September 2028. Says the license allows it to continue its product development roadmaps, as it looks to further move into "key international markets, such as the Americas, UK, Europe and Australia.
Chief Executive Officer Lyn Rees says: "We are delighted to continue our partnership with Illumina following a successful five years of working together to date. This provides us with a good opportunity to further develop exciting market opportunities in NIPT across many key markets."
Current stock price: 0.50 pence, up 2.0% on Wednesday afternoon in London
12-month change: down 94%
By Sophie Rose, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
